SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                           CURRENT REPORT ON FORM 8-K

                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934




                           Date of Report: May 8, 1996
                        (Date of Earliest event reported)


                         *******************************


                          MEDIZONE INTERNATIONAL, INC.
                          ----------------------------

             (Exact name of Registrant as specified in its charter)




  Nevada                        2-93277-D                           87-0412648
  ------                        ---------                           ----------
  State of                      Commission                          IRS Taxpayer
  Incorporation                 Registration No.                    I.D. Number




            123 East 54th Street, Suite 7B, New York, New York 10022
            --------------------------------------------------------
                     Address of Principal executive offices


                  Registrant's telephone number: (212) 421-0303
                                                 --------------





Item 5.           Other Events
                  ------------

     During  the  last  quarter  of  1995,  Medizone  International,  Inc.  (the
"Company")  was  advised by San  Raffaele  Hospital of the  University  of Milan
("Milan") and the Regional  Oncology Center and AIDS Treatment  Center at Aviano
("Aviano") that their respective ethics committees had approved the commencement
of human trials to study the effects of Medizone (the drug) on patients infected
with HIV (in the case of Aviano) and Hepatitis B (chronic-active) trials (in the
case of Milan),  subject to the receipt of specific  affirmative  approvals  for
these trials from the Italian  Ministry of Health.  On May 8, 1996,  the Italian
Ministry of Health issued its approvals,  which were thereafter  communicated to
the Company.  The Italian  Scientific Society for Ozone Oxygen Therapy ("ISSOT")
will supervise  these Phase I clinical trials which were designed by the Company
as classical Phase I trials of its patents (both of Medizone,  the drug, and the
Company's  technology)  to  determine,  in a  dose-ranging  study,  the relative
toxicity of this treatment against surrogate markers of efficacy.  Each of these
trials is designed to take  approximately  one year to complete,  although there
can be no  assurance  that such  time-frame  will be  adhered to once the trials
commence.

     By the terms of the Company's letter agreement with ISSOT,  dated March 23,
1993,  the Company is required to pay for  laboratory  tests  performed  by each
testing  institution  that are outside the scope of the normal realm of clinical
analyses  performed  by the  testing  institutions.  The Company has agreed with
Milan  and  Aviano,  respectively,  that  the  costs  of  these  assays  will be
approximately  U.S. $150,000 for Milan and U.S. $180,000 for Aviano. The Company
is  required  to  commit  to each of  these  respective  fundings  prior  to the
commencement of trials at the particular site. The Company is presently  without
the  financial  wherewithal  to enter into such  binding  commitments  with each
institution  to provide such funding and neither trial will commence  until such
commitment is made by the Company.  The Company is also required to provide each
institution  with ozone  generating,  monitoring and delivery devices for use in
the trials.  On July 1, 1996,  the Company  agreed in principle  with an Italian
manufacturer  to provide  ozone  generating  devices  which  meet the  Company's
specifications for the Italian trials as well as its equipment patent for use in
the  trials to be  commenced  at Milan and  Aviano,  as well as the other  sites
contemplated under the Company's letter agreement with ISSOT. While the terms of
this   agreement   have   been   finalized,   with   the   Company's   financial
responsibilities  thereunder (approximately U.S. $180,000), being subject to the
construction  of an actively  working  prototype  meeting  all of the  Company's
detailed  specifications,  the  Company  presently  does not have the  financial
resources to meet its  obligations  under this  putative  agreement and will not
enter into such agreement until it obtains  financing  sufficient for it to meet
its obligations thereunder.

                                       2


                                   SIGNATURES
                                   ----------

     Pursuant to the  requirements of the Securities Act of 1934, the Registrant
has  duly  caused  this  Current  Report  to be  signed  on  its  behalf  by the
undersigned, one of its officers thereunto duly authorized.

Dated:  New York, NY
        July 1, 1996

                                            MEDIZONE INTERNATIONAL, INC.



                                            By: s/Joseph S. Latino    
                                               ---------------------------
                                                  Joseph S. Latino
                                                  President



                                       3